Express Scripts’ New 340B Rules Will Have Big Impact on Contract Pharmacy and Drug Reimbursement, Providers and Consultants Say

340B covered entities fault Express Scripts for not communicating with them more effectively about changes in its 340B claims identification and reporting requirements, which the entities consider to be major.

340B covered entities say they are deeply concerned about pharmacy benefit manager Express Scripts’ (ESI) requirements, effective Monday, governing what pharmacies in the PBM’s network must do when they identify that a previously submitted claim is 340B-eligible. Last night, ESI told

Read More »

Express Scripts’ New 340B Claims ID Requirement Has Covered Entities Worried

The 340B Coalition told Express Scripts that covered entities cannot comply with its new 340B claims submission and identification requirement absent "a massive investment of financial and human resources." | Shutterstock

Pharmacy benefit manager Express Scripts late yesterday began notifying 340B covered entities by email that, effective March 1, it “will require a new identification method for submitting and identifying 340B eligible claims.”

A health system 340B program manager said this

Read More »

Bausch Health Confirms 340B Rapprochement with AmeriSourceBergen

Bausch Health last week confirmed on HRSA's website that AmeriSourceBergen has resumed distributing Bausch's 340B priced brand products. | Shutterstock

Drug manufacturer Bausch Health last week said on the U.S. Health Resources and Services Administration website that its branded NDCs “will once again be available at the 340B ceiling price” through AmeriSourceBergen Corp. (ABC) “for eligible 340B purchases made by

Read More »

AmeriSourceBergen Has Resumed Distributing 340B-Priced Bausch Health Drugs

340B pricing on Bausch Health products is being restored to AmeriSourceBergen's ordering platforms, 340B Report has learned. | Source: Shutterstock

Drug manufacturer Bausch Health and distributor AmeriSourceBergen Corp. (ABC) apparently have settled their differences and 340B pricing on Bausch Health products is being restored to ABC’s ordering platforms, 340B Report has learned.

Bausch Health blindsided 340B covered entities on

Read More »

Half of Health Care Execs Surveyed Expect Biden to Act on Pharma’s 340B Pricing Denials

Half of health care industry executives surveyed last month think President Biden will take action against drug manufacturers that have stopped offering 340B pricing on their products. | Source: Advis

Half (50 percent) of a sample of health care industry C-suite executives surveyed last month expect the Biden administration to “formally obligate drug manufacturers to offer 340B pricing,” consulting firm Advis reports in its first health care industry leadership survey

Read More »

New Walgreens Leader Will Be Fortune 500’s Sole Black Female CEO

Walgreens Boots Alliance has chosen Roz Brewer to be its new CEO effective March 15. She will be the sole Black woman running a Fortune 500 company.

Walgreens Boots Alliance (WBA) this week appointed veteran business chief executive Rosalind (Roz) Brewer as WBA’s chief executive officer effective March 15. The appointment will make Brewer the sole Black female CEO of a Fortune 500 company.

Brewer most recently

Read More »

340B Providers Blindsided by Bausch Health’s Decision to Drop AmerisourceBergen as Distributor

340B covered entities are scrambling to respond to the fallout from Bausch Health's surprise announcement that it ended its relationship with AmerisourceBergen to distribute its 340B-priced branded products. | Source: Shutterstock

Drug manufacturer Bausch Health blindsided 340B covered entities on New Year’s Eve, announcing that starting the very next day, Jan. 1, more than 200 of its branded products and future branded products would no longer be available through distributor AmerisourceBergen

Read More »

Providers Are Pleased, PhRMA Isn’t, With Becerra and State AGs’ 340B Letter to Azar

Editor’s note—A cascade of breaking 340B news developments over the past seven days—Amgen’s orphan drug action, HRSA’s dispute resolution final rule, the hospital lawsuit against HHS, the state attorneys general letter to HHS and the new GAO report—forced us to

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live